Answers are grounded in this paper and cite their sources.
Background: We report a case of severe vasoplegia that was unresponsive to triple vasopressor therapy but showed marked hemodynamic improvement following intravenous hydroxocobalamin administration in a patient with underlying cirrhosis.Case Report: A 63-year-old Asian woman with no remarkable medical history presented with a 1-week history of headaches and neck stiffness. Imaging revealed an aneurysmal subarachnoid hemorrhage. Shortly after initiating oral nimodipine, she developed profound hypotension that was refractory to fluid resuscitation and high-dose triple vasopressor support. After excluding other causes of distributive shock, she received 5 g of intravenous hydroxocobalamin for suspected nimodipine-induced vasoplegia, which resulted in the rapid stabilization of blood pressure. No adverse effects were observed apart from transient chromaturia. Subsequent workup revealed cirrhosis secondary to chronic hepatitis B infection.Conclusion: Nimodipine remains a mainstay in the management of subarachnoid hemorrhage to prevent delayed cerebral ischemia; however, severe catecholamine-resistant hypotension is an uncommon adverse effect, particularly in patients with impaired hepatic metabolism. Drug-induced vasoplegia should be considered in cases of unexplained vasodilatory shock following nimodipine administration. This case illustrates the successful use of hydroxocobalamin as rescue therapy under such circumstances.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: